Evidence map›Paper›PMID 37255756›Full record

ArticleFrontiers in public health2023

Surveillance of carbapenem-resistant organisms using next-generation sequencing.

Katelin V Gali, Rachael M St Jacques, Cheyanne I D Daniels, Allison O'Rourke, Lauren Turner

Open access · goldAbstract read
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Katelin V GaliDivision of Consolidated Laboratory Services, Department of General Services, Richmond, VA, United States.
Rachael M St JacquesDivision of Consolidated Laboratory Services, Department of General Services, Richmond, VA, United States.
Cheyanne I D DanielsDivision of Consolidated Laboratory Services, Department of General Services, Richmond, VA, United States.
Allison O'RourkeDivision of Clinical Epidemiology, Office of Epidemiology, Virginia Department of Health, Richmond, VA, United States.
Lauren TurnerDivision of Consolidated Laboratory Services, Department of General Services, Richmond, VA, United States.
Department of General Services · USVirginia Department of Health · US

Funding

ACL HHS U01CK000555NCEZID CDC HHS U01 CK000555
6 · The paper itself

Abstract

The genomic data generated from next-generation sequencing (NGS) provides nucleotide-level resolution of bacterial genomes which is critical for disease surveillance and the implementation of prevention strategies to interrupt the spread of antimicrobial resistance (AMR) bacteria. Infection with AMR bacteria, including Gram-negative Carbapenem-Resistant Organisms (CRO), may be acute and recurrent-once they have colonized a patient, they are notoriously difficult to eradicate. Through phylogenetic tools that assess the single nucleotide polymorphisms (SNPs) within a pathogen genome dataset, public health scientists can estimate the genetic identity between isolates. This information is used as an epidemiologic proxy of a putative outbreak. Pathogens with minimal to no differences in SNPs are likely to be the same strain attributable to a common source or transmission between cases. These genomic comparisons enhance public health response by prompting targeted intervention and infection control measures. This methodology overview demonstrates the utility of phenotypic and molecular assays, antimicrobial susceptibility testing (AST), NGS, publicly available genomics databases, and open-source bioinformatics pipelines for a tiered workflow to detect resistance genes and potential clusters of illness. These methods, when used in combination, facilitate a genomic surveillance workflow for detecting potential AMR bacterial outbreaks to inform epidemiologic investigations. Use of this workflow helps to target and focus epidemiologic resources to the cases with the highest likelihood of being related.

Indexed as

Anti-Infective AgentsCarbapenemsGenome, BacterialHigh-Throughput Nucleotide SequencingHumansPhylogenyAnti-Infective AgentsCarbapenemsantimicrobial resistancecarbapenem-resistant organismsnext-generation sequencingoutbreaksurveillance

Identifiers

PMID37255756
PMCPMC10225708
OpenAlexW4378783066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.